Literature DB >> 2554870

Positive inotropic stimulation in the normal and insufficient human myocardium.

E Erdmann1, M Böhm.   

Abstract

Cardiac alpha- and beta-adrenoceptors and the positive inotropic effects of several adenylate cyclase dependent and independent agents have been measured in papillary muscle strips from patients without, as well as with moderate and severe heart failure. The number of beta-adrenoceptors was found to be decreased depending on the degree of heart failure. This does not apply to alpha-adrenoceptors, which remain unchanged. The antagonist affinity of adrenoceptors for the different ligands did not change in heart failure. Maximal increases in force of contraction were measured after raising Ca++ up to 15 mM in the muscle strips. In healthy human myocardium, isoprenaline, dobutamine, IBMX or cardiac glycosides increase force of contraction to the same maximal values as Ca++ does. However, in cardiac tissue from heart failure patients, positive inotropic agents which increase intracellular cAMP or are cAMP-dependent are less effective than Ca++. Furthermore, the results seem to indicate a homologous (agonist specific) downregulation of receptors in moderate heart failure and a heterologous downregulation in severe heart failure. Thus, many well known positive inotropic drugs lose their effectiveness just when they are needed most: in severe heart failure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554870     DOI: 10.1007/BF02650352

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  21 in total

1.  Reduction in the activity of the stimulatory guanine nucleotide-binding protein in the myocardium of spontaneously hypertensive rats.

Authors:  T Murakami; T Katada; H Yasuda
Journal:  J Mol Cell Cardiol       Date:  1987-02       Impact factor: 5.000

2.  Homologous vs. heterologous desensitization of the adenylate cyclase system in heart cells.

Authors:  C Reithmann; K Werdan
Journal:  Eur J Pharmacol       Date:  1988-09-01       Impact factor: 4.432

3.  Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium.

Authors:  M Böhm; D Beuckelmann; L Brown; G Feiler; B Lorenz; M Näbauer; B Kemkes; E Erdmann
Journal:  Eur Heart J       Date:  1988-08       Impact factor: 29.983

Review 4.  Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors.

Authors:  R J Lefkowitz; M G Caron; G L Stiles
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

Review 5.  Biochemical, structural and mechanical defects of the failing myocardium.

Authors:  W H Newman
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

6.  Cardiac pumping capability and prognosis in heart failure.

Authors:  L B Tan
Journal:  Lancet       Date:  1986-12-13       Impact factor: 79.321

Review 7.  Beta-adrenergic function in heart muscle disease and heart failure.

Authors:  M R Bristow; N E Kantrowitz; R Ginsburg; M B Fowler
Journal:  J Mol Cell Cardiol       Date:  1985-07       Impact factor: 5.000

8.  Tolerance to dobutamine after a 72 hour continuous infusion.

Authors:  D A Unverferth; M Blanford; R E Kates; C V Leier
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

9.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

10.  Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.

Authors:  W S Colucci; A R Denniss; G F Leatherman; R J Quigg; P L Ludmer; J D Marsh; D F Gauthier
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

View more
  3 in total

1.  Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure.

Authors:  C L Perreault; N L Hague; E Loh; I M Hunneyball; M F Sim; J P Morgan
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

2.  Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure.

Authors:  C L Perreault; R P Shannon; K Komamura; S F Vatner; J P Morgan
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

3.  Cardiac and Vascular α1-Adrenoceptors in Congestive Heart Failure: A Systematic Review.

Authors:  Gizem Kaykı-Mutlu; Olga Papazisi; Meindert Palmen; A H Jan Danser; Martin C Michel; Ebru Arioglu-Inan
Journal:  Cells       Date:  2020-11-04       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.